** Shares of AnaptysBio ANAB.O fall as much as 38.5% to an over one-year low of $14.20
** Stock set for worst day since Nov 2019, if losses hold
** Co says it will discontinue development of its eczema drug ANB032 after it failed to meet the goals of a mid-stage trial
** Drug did not meet the main goal of a proportion of patients achieving an at least 75% improvement of symptoms on an eczema severity index
** ANAB will focus on the rest of its autoimmune portfolio, which includes drugs for rheumatoid arthritis and a type of inflammatory bowel disease - CEO
** Up to last close, stock down 30.6% YTD
(Reporting by Puyaan Singh)
((Puyaan.Singh@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。